breast cancer
Conditions
Interventions
PH-FDC-SC group:no
P-IV+H-IV group:None
P-IV + H-SC group:None
Sponsors
Cancer Hospital Affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1)Agree to participate in the study and sign the informed consent form; 2)Female patients with breast cancer aged >=18 years; 3)Pathological molecular typing is HER2 +; 4)Complete tumor clinical pathology information; 5)Patients who received subcutaneous or intravenous PH injections from 7th to 18th after receiving combination chemotherapy (to ensure that any deviations from IV and SC dosing were similar).
Exclusion criteria
Exclusion criteria: 1)History of previous treatment for other malignancies; 2)Incomplete tumor clinical pathology information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time savings for HCP with PH-FDC-SC vs P-IV+H-IV and P-IV+H-SC in the adjuvant treatment of HER2-positive EBC patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time savings for patients with PH-FDC-SC vs P-IV+H-IV and P-IV+H-SC in the adjuvant treatment of HER2-positive EBC .;Consumption usage and cost of drug waste; | — |
Countries
China
Contacts
Public ContactMeng Yingtao
Cancer Hospital Affiliated to Shandong First Medical University
Outcome results
None listed